GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 411.83 %

Biogen Idec Inc (BIIB) upgraded to Buy with price target $70 by BWS Financial

Posted on: Tuesday,  Jan 15, 2008  8:25 AM ET by BWS Financial

BWS Financial rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 01/15/2008, when the stock price was $59.49. Since
then, Biogen Idec Inc has gained 411.83% as of 01/07/2016's recent price of $304.49.
If you would have followed this BWS Financial's recommendation on BIIB, you would have gained 411.83% of your investment in 2914 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

· BWS Financial is a Los Angeles based independent stock research firm, which focuses primarily on undervalued companies with little or no street coverage, within the biotechnology, healthcare and technology industries. · BWS Financial focuses on companies that hold much potential in their industries, either through their product pipeline or technological innovations. · BWS Financial’s strategy is not to only specialize in a particular group of stocks, but to also provide investors with insight into other ideas where there is considerable misvaluation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/15/2008 8:25 AM Buy
None
59.49 70.00
as of 12/24/2008
1 Week down  -8.00 %
1 Month down  -9.64 %
3 Months down  -2.82 %
1 YTD down  -3.25 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/13/2007 9:25 AM Hold
None
70.64 72.00
10/16/2007 9:39 PM Sell
None
78.86 72.00
8/31/2007 9:25 AM Hold
None
64.25 64.00
8/13/2007 9:25 AM Buy
None
57.30 64.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy